A New MCAS Medication with Great Potential
Understanding Amlexanox:
Amlexanox belongs to the tricyclic amine carboxylic acid class, akin to sodium cromoglycate (Cromolyn®; Gastrocrom®; Nasalcrom®). It acts as an effective anti-inflammatory, antiallergic, and immunomodulator, making it valuable beyond its initial approval.
Versatility and Benefits:
Anti-Inflammatory Power: Amlexanox reduces inflammation by targeting pathways like mTOR and NF-κB, crucial biomarkers in inflammatory processes. This action is vital for conditions ranging from asthma and rhinitis to complex inflammatory disorders.
Safety Profile: Studies have shown that Amlexanox, even at higher doses (10mg/kg/day in dogs), exhibits minimal adverse effects, making it a safer alternative to corticosteroids like Prednisone.
Broad Application: Beyond its FDA-approved uses, Amlexanox has been explored for COVID-19-related multi-organ damage, showing promise in managing systemic inflammation.
Metabolic Benefits: It improves insulin resistance, aids in fat metabolism, and enhances cellular energy balance through AMPK activation. This is crucial for conditions like type 2 diabetes and fatty liver disease.
Reduced Dependency: By modulating macrophages, balancing Th1 responses, and inhibiting histamine and leukotriene release, Amlexanox can reduce reliance on multiple medications that have higher side effects and costs.
Support for MCAS Patients: One of the standout features of Amlexanox is its ability to modulate mast cell activity. Mast Cell Activation Syndrome (MCAS) is a condition where mast cells release excessive amounts of chemicals like histamine, leading to symptoms such as itching, swelling, and allergic-type reactions. Amlexanox has been shown to reduce the release of these mediators, including histamines and leukotrienes, in mast cells, neutrophils, and monocytes. This makes it a valuable treatment option for those suffering from MCAS, providing relief and improving quality of life.
Part of Our MCAS Program:
We are thrilled to include Amlexanox as a key component of our MCAS program at LDN Direct. Our program is designed to offer a comprehensive approach to managing MCAS, focusing on reducing symptoms and improving patient outcomes. By incorporating Amlexanox, we aim to provide a more effective, streamlined treatment option that minimizes the need for multiple medications with significant side effects.
As we integrate Amlexanox into our practice, we look forward to exploring its benefits with you, our valued patients. Whether you're dealing with MCAS or other inflammatory conditions, together we can harness its therapeutic potential to achieve better health outcomes and improved quality of life.
Thank you for entrusting us with your care. Please don't hesitate to reach out with any questions or to discuss whether Amlexanox may be right for you.
How does the MCAS program work?
WHAT’S INCLUDED
—
4 consultations via video chat with Dr. Zalzala and Jade over 6 months
+
Recommendations on which medications are right for you, titration instructions to your best dose, a 6 month supply of medication called into the pharmacy of your choice
+
Full support via EMR
$189*
*includes consultation fees only, the cost of the medications themselves is paid directly to your pharmacy
How to get started:
Make payment for the program and book your initial consultation with Jade. (payment must be made in order for your program request to be approved).
2. Meet with Jade to discuss your current medicaitons and work together to determine which MCAS medication might be the best fit for you.
3. Meet with Dr. Zalzala to get final input and approval for your medication, and to choose a pharmacy. A $99 appointment fee will be charged to hold your appointment with Dr. Zalzala, but will be refunded once you meet with him.
4. Use your two remaining meeting to discuss progress and further treatment options over the next 6 months.
5. Request your refills every 6 months as needed
Ready to join our MCAS program? Get started by clicking below!